Future studies should incorporate in vitro and in vivo experiments to elucidate the mechanistic pathways and assess the efficacy of PI3K-Akt inhibitors and vitamin D supplementation in improving prognosis for glioma patients, particularly those affected by COVID-19. This evidence concerns the gene AKT1 and COVID-19.